UnknownPhase 4ketamine

Effects of Esketamine on Postpartum Depression

Sponsored by Qinghai University

NCT ID
NCT05229913
Target Enrollment
500 participants
Start Date
2022-02-20
Est. Completion
2023-06-30

About This Study

Different concentrations of Esketamine were used after cesarean section. Through the evaluation of postoperative psychological status and analgesic effect, the optimal dosage of Esketamine to exert the effects of depression and analgesia was analyzed.

Conditions Studied

Postpartum Depression

Interventions

  • Esketamine is not added
  • Esketamine 0.2mg/kg
  • Esketamine 0.4mg/kg
  • Esketamine 0.6mg/kg
  • Esketamine 0.8mg/kg

Eligibility

Sex:FEMALE
Age:25 Years - 35 Years
Healthy Volunteers:Yes
View full eligibility criteria
Inclusion Criteria:

1. All participating patients signed an informed consent form;
2. Age 25-35 years old;
3. BMI≤35kg/m2;
4. ASA classification I or II;
5. Ultrasound showed a single pregnancy in the uterus Fetus, placental maturity grade Ⅱ+

Exclusion Criteria:

1. Unable or unwilling to sign the consent form, or unable to follow the research procedures;
2. History of thyroid disease;
3. A history of local anesthetic allergy;
4. A history of addiction or abuse to opioids and ketamine;
5. Preoperative mental illness; severe eclampsia;
6. Abnormal ECG, hypertension and severe heart Medical history
7. There are other contraindications to the use of esketamine

This trial is not recruiting

This study is currently not accepting new participants.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source